Margaret Chu-Moyer Ph.D.

Margaret Chu-Moyer joined Amgen in 2009 as the head of the Cambridge, MA Medicinal Chemistry group. In 2014, her role expanded to include all of Amgen Medicinal Chemistry, and in 2017, she became head of Amgen's Chemistry, Characterization, Technology & Externalization group. Margaret's organization is accountable for advancing the small molecule portfolio for which recent clinical candidates include the Mcl-1 inhibitors, AMG 176 and AMG 397, the KIF18A inhibitor, AMG 650, and the KRAS G12C inhibitor AMG 510 (LUMAKRAS™), among others.  Margaret received her B.S. in Chemistry from the University of California, Berkeley and a Ph.D. in Organic Chemistry from Yale University, where she trained in the area of natural products total synthesis in the laboratory of Professor Samuel Danishefsky.  Margaret was recently honored as one of 2019's Fiercest Women in Life Sciences.